DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is offering its BRAIN AGE® Brain Health AI Platform to investigate the impact of weight loss drugs, like Semaglutide, on brain function. This comes after a study showed Semaglutide doesn't negatively impact brain health and is associated with lower cognitive problems and less nicotine dependence.
The global market for obesity drugs is expected to reach $105 billion by 2030. BRAIN AGE® aims to identify potential brain health issues and gain insights into brain function while taking weight loss drugs. The platform uses a low-cost EEG headset and machine learning to estimate brain age and assess cognitive health.
Clinical validation of BRAIN AGE® has shown promising results in screening for age-related vulnerabilities and assessing the risk of developing Alzheimer's disease and other neurological issues.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) sta offrendo la sua BRAIN AGE® Piattaforma AI per la Salute Cerebrale per investigare l'impatto dei farmaci per la perdita di peso, come il Semaglutide, sulla funzione cerebrale. Questo arriva dopo che uno studio ha dimostrato che il Semaglutide non ha effetti negativi sulla salute cerebrale ed è associato a minori problemi cognitivi e a una ridotta dipendenza dalla nicotina.
Il mercato globale dei farmaci per l'obesità è previsto raggiungere 105 miliardi di dollari entro il 2030. BRAIN AGE® mira a identificare potenziali problemi di salute cerebrale e a ottenere intuizioni sulle funzioni cerebrali durante l'assunzione di farmaci per la perdita di peso. La piattaforma utilizza una cuffia EEG a basso costo e l'apprendimento automatico per stimare l'età cerebrale e valutare la salute cognitiva.
La validazione clinica di BRAIN AGE® ha mostrato risultati promettenti nello screening delle vulnerabilità legate all'età e nella valutazione del rischio di sviluppare la malattia di Alzheimer e altri problemi neurologici.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) está ofreciendo su BRAIN AGE® Plataforma de IA para la Salud Cerebral para investigar el impacto de los medicamentos para la pérdida de peso, como el Semaglutide, en la función cerebral. Esto se produce después de que un estudio mostró que el Semaglutide no impacta negativamente la salud cerebral y está asociado con menores problemas cognitivos y menos dependencia de la nicotina.
Se espera que el mercado global de medicamentos para la obesidad alcance 105 mil millones de dólares para 2030. BRAIN AGE® tiene como objetivo identificar posibles problemas de salud cerebral y obtener información sobre la función cerebral mientras se toman medicamentos para la pérdida de peso. La plataforma utiliza un auricular EEG de bajo costo y aprendizaje automático para estimar la edad cerebral y evaluar la salud cognitiva.
La validación clínica de BRAIN AGE® ha mostrado resultados prometedores en el cribado de vulnerabilidades relacionadas con la edad y en la evaluación del riesgo de desarrollar enfermedad de Alzheimer y otros problemas neurológicos.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF)는 체중 감량 약물인 세마글루타이드가 뇌 기능에 미치는 영향을 조사하기 위해 자사의 BRAIN AGE® 두뇌 건강 AI 플랫폼을 제공하고 있습니다. 이는 세마글루타이드가 뇌 건강에 부정적인 영향을 미치지 않으며, 인지 문제를 줄이고 니코틴 의존도가 낮아진다는 연구 결과에 따른 것입니다.
전 세계 비만 약물 시장은 2030년까지 1,050억 달러에 이를 것으로 예상됩니다. BRAIN AGE®는 체중 감량 약물 사용 중 발생할 수 있는 뇌 건강 문제를 식별하고 뇌 기능에 대한 통찰을 얻는 것을 목표로 합니다. 이 플랫폼은 저렴한 EEG 헤드셋과 기계 학습을 사용하여 뇌 나이를 추정하고 인지 건강을 평가합니다.
BRAIN AGE®의 임상 검증은 연령 관련 취약성을 선별하고 알츠하이머병 및 기타 신경학적 문제 발병 위험을 평가하는 데 유망한 결과를 보였습니다.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) propose sa BRAIN AGE® Plateforme AI pour la Santé Cérébrale pour enquêter sur l'impact des médicaments anti-obésité, tels que le Semaglutide, sur la fonction cérébrale. Cela fait suite à une étude montrant que le Semaglutide n'a pas d'impact négatif sur la santé cérébrale et est associé à moins de problèmes cognitifs et à une dépendance réduite à la nicotine.
Le marché mondial des médicaments contre l'obésité devrait atteindre 105 milliards de dollars d'ici 2030. BRAIN AGE® vise à identifier d'éventuels problèmes de santé cérébrale et à obtenir des aperçus sur la fonction cérébrale lors de la prise de médicaments contre la perte de poids. La plateforme utilise un casque EEG à faible coût et l'apprentissage automatique pour estimer l'âge cérébral et évaluer la santé cognitive.
La validation clinique de BRAIN AGE® a montré des résultats prometteurs dans le dépistage des vulnérabilités liées à l'âge et dans l'évaluation du risque de développer la maladie d'Alzheimer et d'autres problèmes neurologiques.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) bietet seine BRAIN AGE® Gehirn Gesundheits-AI-Plattform an, um die Auswirkungen von Gewichtsverlustmedikamenten wie Semaglutid auf die Gehirnfunktion zu untersuchen. Dies geschieht, nachdem eine Studie gezeigt hat, dass Semaglutid die Gehirngesundheit nicht negativ beeinflusst und mit weniger kognitiven Problemen und einer geringeren Nikotinabhängigkeit assoziiert ist.
Der globale Markt für Adipositas-Medikamente wird bis 2030 auf 105 Milliarden Dollar anwachsen. BRAIN AGE® zielt darauf ab, potenzielle Probleme der Gehirngesundheit zu identifizieren und Einblicke in die Gehirnfunktion während der Einnahme von Gewichtsverlustmedikamenten zu gewinnen. Die Plattform verwendet ein kostengünstiges EEG-Headset und maschinelles Lernen, um das Gehirnalter zu schätzen und die kognitive Gesundheit zu bewerten.
Die klinische Validierung von BRAIN AGE® hat vielversprechende Ergebnisse bei der Früherkennung altersspezifischer Verwundbarkeiten und der Bewertung des Risikos, an Alzheimer und anderen neurologischen Erkrankungen zu erkranken, gezeigt.
- Expansion of BRAIN AGE® platform into the lucrative weight loss drug market
- Global obesity drug market expected to reach $105 billion by 2030
- Clinical validation shows BRAIN AGE® effectiveness in screening for age-related vulnerabilities
- Low-cost and easy-to-use EEG headset for data collection
- None.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, on brain function. In a recently published study, Semaglutide, a GLP-1 receptor agonist that has been approved by the FDA and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®, showed that it does not appear to impact brain health negatively and is associated with lower risk of cognitive problems and less nicotine dependence.1
Future research on brain activity while taking weight loss drugs may provide insight into brain function and could offer new opportunities for personalized treatment regimens for overall brain health.
Fabio Chianelli, CEO of DiagnaMed, commented: “We are expanding the use of BRAIN AGE® Brain Health AI Platform as a potential clinical tool for investigating the impact of weight loss drugs, such as semaglutide, on brain function. Clinical studies for weight loss and the opportunity to know more about how the brain functions during a set treatment period could unlock personalized treatment regimens to maintain or improve overall brain health.”
Opportunity of Brain Health AI Platform in Weight Loss
According to Morgan Stanley Research, the global market for obesity drugs is expected to reach
Based on research studies at Drexel University and the University of Miami, BRAIN AGE® Brain Health AI aims to ‘raise a red flag’ for potential brain health issues. It can also help gain insights into brain function, memory, and thinking ability while taking weight loss drugs over some time. Study objectives can measure brain change over a specific timeframe and explore changes in executive functioning, quality of life, mood, and eating behaviour related to EEG data.
Interested clinics, hospitals, clinical research organizations, biotech, and pharmaceutical companies investigating weight loss drugs and would like to understand how they impact the brain can obtain more information on the BRAIN AGE® Brain Health AI Platform by visiting BrainAge.io.
Clinical Validation of BRAIN AGE® Brain Health AI Platform
BRAIN AGE® Brain Health AI can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram headset and calculating the data with a proprietary machine-learning model. In addition, BRAIN AGE® Brain Health AI can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help decrease cognitive decline development or progression.
In a first-of-a-kind peer-reviewed paper in Frontiers in Neuroergonomics, titled “Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization”3, BRAIN AGE®, as announced in a press release by Drexel University, Prof. Kounios was quoted regarding the clinical potential of BRAIN AGE®: “It can be used as a relatively inexpensive way to screen large numbers of people for vulnerability to age-related. And because of its low cost, a person can be screened at regular intervals to check for changes over time,” Kounios said. “This can help to test the effectiveness of medications and other interventions. And healthy people could use this technique to test the effects of lifestyle changes as part of an overall strategy for optimizing brain performance.”4
From the University of Miami Comprehensive Center for Brain Health, the BRAIN AGE® brain health assessment portion is designed to assess a patient’s risk for developing Alzheimer’s disease (“AD”) and other neurological issues, through an advanced series of tests that determine the risk for dementia by combining three measures — a Resilience Index (“RI”), a Vulnerability Index (“VI”) and a Number-Symbol Coding Task (“NSCT”). The results, when combined, help assess the risk for developing AD and other related conditions. Essentially, it is intended to “take a snapshot” of a patient’s brain health. In a cross-sectional study, Galvin and colleagues evaluated 230 participants (71 controls, 71 with mild cognitive impairment, 88 with AD and related disorders). Researchers determined VI and RI scores from physical assessments, lifestyle questionnaires, demographics, medical history and neuropsychological examination, including the NSCT. Results showed that participants with abnormal test scores were
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a healthcare technology company focused on brain health using AI. DiagnaMed is commercializing BRAIN AGE® Brain Health AI Platform, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and six months ended March 31, 2024 (“MD&A”), dated May 29, 2024, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
Footnotes:
- https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00305-5/fulltext#secsectitle0010
- https://www.morganstanley.com/ideas/obesity-drugs-market-expanded-opportunity
- Kounios John, Fleck Jessica I., Zhang Fengqing, Oh Yongtaek. Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization. Frontiers in Neuroergonomics. 2024; Volume 5. DOI=10.3389/fnrgo.2024.1340732. https://www.frontiersin.org/articles/10.3389/fnrgo.2024.1340732.
- https://drexel.edu/news/archive/2024/April/New-AI-Technology-Estimates-Brain-Age-Using-Low-Cost-EEG-Device
- Kleiman, Michael J et al. “The Brain Health Platform: Combining Resilience, Vulnerability, and Performance to Assess Brain Health and Risk of Alzheimer's Disease and Related Disorders.” Journal of Alzheimer's disease: JAD vol. 90,4 (2022): 1817-1830. doi:10.3233/JAD-220927
FAQ
What is DiagnaMed's BRAIN AGE® Brain Health AI Platform being used for regarding weight loss drugs?
How large is the projected global market for obesity drugs by 2030?
What is the stock symbol for DiagnaMed Holdings Corp.?
How does the BRAIN AGE® Brain Health AI Platform assess brain health?
